ReSynapse Therapeutics
Coming Soon

Multi-Target Neuropsychiatric Drugs via Computational Drug Design

ReSynapse is a biotechnology company developing small-molecule multi-target therapeutics for treatment-resistant depression and anxiety disorders. Using computational chemistry, we systematically design or identify single-molecule compounds that simultaneously target specific combinations of serotonin (5-HT) receptors to modulate serotonin precisely.Unmet Medical Need
Treatment-resistant depression affects 2.8 million Americans and 11 million Europeans, achieving only 16.7% remission rates with current therapies.
Current Drugs' Limitations:
• SSRIs/SNRIs: 4-6 weeks onset, significant side effects (weight gain, sexual dysfunction, emotional blunting), 30% treatment-resistance;
• Psychedelics: Variable efficacy, hallucinogenic risks, and regulatory challenges.
• Existing multi-target drugs (vortioxetine, brexpiprazole): Non-selective "shotgun" polypharmacology causes side effects, and limited efficacyOur Solution
ReSynapse develops small molecules that precisely target specific combinations of serotonin receptors, with validated mechanisms, aiming for fast-acting, long-lasting efficacy, and reduced side effects.
Our Process:
1. Identify validated receptor combinations for targeting, demonstrating complementary antidepressant mechanisms
(supported by 25+ preclinical studies)
2. Systematically design compounds with predetermined receptor engagement profiles using proprietary computational methods
3. Selective modulation: Target serotonin receptors exclusively, avoiding dopamine and adrenergic receptors
that cause side effects in non-selective drugs.
Result: Multi-target precision vs. non-selective polypharmacology
.....................................................
Scientific Foundation
Our lead program targets four specific serotonin receptors, each with established individual antidepressant mechanisms in peer-reviewed literature. Clinical evidence demonstrates that multi-target combinations produce superior outcomes compared to single-target approaches, with regulatory precedent established through FDA-approved CNS multi-target therapeutics (vortioxetine, brexpiprazole).
Computational Platform:
• Structural analysis: 39 serotonin receptor structures systematically analyzed
• Ligand database: Millions of compounds evaluated for multi-target potential
• Proprietary algorithms: Custom computational methods for rational multi-target design.
...........................................................
Innovation & Differentiation
Science-first approach: Four specific serotonin receptors with proven individual antidepressant mechanisms, driven by validated biology, not empirical screening or generative AI +
Systematic design capabilities: Proprietary computational methodologies enable systematic multi-target design, impossible with standard tools +
Selective multi target: integration of the complex functionality of the serotonin system in the brain.
...........................................................
Current Status, Oct 2025
Multiple proprietary drug candidates identified targeting the 4-receptor combination for treatment-resistant depression. The lead screening phase is active to select optimal compounds for POC validation & preclinical development.IP strategy: Patent filing planned within 4 months to protect novel compounds and multi-target design methodologies
........................................................
Team
• CEO: Dr. Dorit Cohen Carmon: 10+ years CNS development, 2x proven biotech execution
• CTO, Dr. Itai Bloch: 15+ years pharmaceutical computational chemistry, proprietary multi-target methodologies, and receptor pharmacology.
• Scientific Advisor, Prof. Alexandre Varnek: 2024 Herman Skolnik Award winner, world leader in computational drug design with 14,000+ citations
...........................................................
Vision & Opportunity Our systematic receptor-targeting methodology enables expansion across anxiety, PTSD, and other neuropsychiatric disorders. The platform approach addresses complex receptor networks that single-target approaches cannot treat effectively.
..........................................................
Funding & Milestones
Current Status, Oct 2025:
- Non-dilutive grants secured through competitive peer review
- Seed fundraising open for POC validation, lead optimization, and preclinical developmentSeed Stage Objectives (24 months):
- Lead candidate optimization and experimental validation
- IP filing and patent prosecution
- Computational infrastructure expansion
- Preclinical development pathway preparation

Multi-Target Neuropsychiatric Therapies for Mood Disorders via Computational Drug Design